| breast cancer - HER2-positive | breast cancer - triple negative | ||||
| es-BC - HER2 positive - (neo)adjuvant (NA) | mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | es-BC - TNBC - NA - all population | es-BC - TNBC - NA - PDL1 positive | |
| atezolizumab based treatment | IMpassion-050 IMpassion-050 IMpassion-050 | ALEXANDRA/IMpassion-030 | |||
| atezolizumab plus carboplatin plus nab-paclitaxel | NeoTRIPaPDLA | ||||
| atezolizumab plus nab-paclitaxel | IMpassion-130 ... | IMpassion-130 ... | |||
| atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | IMpassion-031 ... | IMpassion-031 ... | |||
| atezolizumab plus paclitaxel | IMpassion-131 ... | IMpassion-131 ... | |||
| atezolizumab plus SoC | IMpassion-132 | ||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
